Published in Antimicrob Agents Chemother on December 01, 1972
Overview of medically important antifungal azole derivatives. Clin Microbiol Rev (1988) 3.33
Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing. J Clin Microbiol (1988) 1.71
Antifungal resistance and new strategies to control fungal infections. Int J Microbiol (2011) 1.44
Disk agar diffusion susceptibility testing of yeasts. Antimicrob Agents Chemother (1978) 1.35
Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use. Antimicrob Agents Chemother (1984) 1.21
Inhibition of potentially pathogenic yeastlike fungi by clotrimazole in combination with 5-fluorocytosine or amphotericin B. Antimicrob Agents Chemother (1976) 1.20
Potent antimalarial activity of clotrimazole in in vitro cultures of Plasmodium falciparum. Proc Natl Acad Sci U S A (2000) 1.12
Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug Metab Dispos (2008) 0.98
Comparison of vaginal flora after treatment with a clotrimazole 500 mg vaginal pessary or a fluconazole 150 mg capsule for vaginal candidosis. Genitourin Med (1991) 0.94
Cavamax W7 composite ethosomal gel of clotrimazole for improved topical delivery: development and comparison with ethosomal gel. AAPS PharmSciTech (2012) 0.79
The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Management of mycoses in neutropenic patients: a brief history, 1960-2008. J Antimicrob Chemother (2009) 0.75
New antifungal therapy in ophthalmology. Trans Am Ophthalmol Soc (1973) 0.75
Therapy of fungal infections. Bull N Y Acad Med (1982) 0.75
Systemic fungal infections complicating renal transplantation and immunosuppressive therapy. Clinical, microbiologic, neurologic and pathologic features. Am J Med (1967) 4.08
Fungal infections complicating acute leukemia. J Chronic Dis (1966) 4.07
5-fluorocytosine: an oral antifungal compound. A report on clinical and laboratory experience. Ann Intern Med (1972) 3.55
[1st clinical experience with a new oral antimycotic in systemic mycoses]. Dtsch Med Wochenschr (1969) 2.46
5-fluorocytosine in the treatment of mycotic infections. Ann Intern Med (1972) 2.40
Infectious complications after cardiac transplantation in man. Ann Intern Med (1971) 2.37
BAY b 5097, a new orally applicable antifungal substance with broad-spectrum activity. Antimicrob Agents Chemother (Bethesda) (1969) 1.91
Problems in the diagnosis and treatment of systemic candidiasis. J Infect Dis (1972) 1.83
In vitro sensitivity of Torulopsis glabrata to amphotericin B, 5-fluorocytosine, and clotrimazole (Bay 5097). Appl Microbiol (1971) 1.60
Fatal infections in childhood leukemia. Am J Dis Child (1971) 1.59
Chemotherapeutic evaluation of clotrimazole (Bay b 5097, 1 (o-chloro- - -diphenylbenzyl) imidazole). Appl Microbiol (1971) 1.26
Oral antibiotic prophylaxis in protected environment units: effect of nonabsorbable and absorbable antibiotics on the fecal flora. Antimicrob Agents Chemother (1972) 1.15
Bay B 5097, a new orally applicable antifungal substance with broadspectrum activity. Preliminary clinical and laboratory experiences in children. Acta Paediatr Scand (1971) 1.10
AMPHOTERICIN B TOXICITY; CHANGES IN RENAL MORPHOLOGY. Ann Intern Med (1964) 1.06
In vivo studies with Bay b 5097. Antimicrob Agents Chemother (Bethesda) (1970) 0.97
Infectious complications in bone marrow transplant patients. Br Med J (1971) 0.93
Saccharomyces fungemia. Chest (1970) 0.92
Pulmonary aspergillomata in a child treated with clotrimazole. Br Med J (1971) 0.89
Persistent fungemia caused by Torulopsis glabrata: treatment with amphotericin B. Am J Clin Pathol (1970) 0.80
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Mezlocillin: in vitro studies of a new broad-spectrum penicillin. Antimicrob Agents Chemother (1977) 7.24
Infections caused by Pseudomonas aeruginosa. Rev Infect Dis (1983) 7.19
Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity. Antimicrob Agents Chemother (1979) 5.81
In vitro studies of semisynthetic alpha-(substituted-ureido) penicillins. Appl Microbiol (1971) 5.23
Proceedings: Causes of death in cancer patients. Cancer (1974) 4.56
Infections in cancer patients. Results with gentamicin sulfate therapy. Cancer (1972) 4.47
Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother (1991) 4.36
Fungal infections complicating acute leukemia. J Chronic Dis (1966) 4.07
Azlocillin: in vitro studies of a new semisynthetic penicillin. Antimicrob Agents Chemother (1977) 4.00
Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol (1994) 3.94
Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother (1988) 3.92
In vitro activity of carbenicillin against gram-negative bacilli. J Bacteriol (1968) 3.41
Piperacillin: in vitro evaluation. Antimicrob Agents Chemother (1978) 3.21
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis (2000) 2.78
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep (1972) 2.71
In vitro evaluation of Ro 13-9904. Antimicrob Agents Chemother (1980) 2.67
Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis (2002) 2.63
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis (1993) 2.51
Candidiasis in cancer patients. Am J Med (1984) 2.48
Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis (1991) 2.47
Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288). Antimicrob Agents Chemother (1973) 2.47
PC-904, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.46
Carbenicillin therapy for pseudomonas infections. JAMA (1971) 2.40
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin. Appl Microbiol (1971) 2.35
Carbenicillin therapy of gram-negative bacilli infections. Am J Med Sci (1969) 2.25
Comparative in vitro study of SQ26,776. Antimicrob Agents Chemother (1982) 2.23
In vitro evaluation of cefoperazone. Antimicrob Agents Chemother (1980) 2.22
Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med (1985) 2.17
Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis (1993) 2.17
Ciprofloxacin-induced nephrotoxicity in patients with cancer. Arch Intern Med (1993) 2.16
New spectrum of fungal infections in patients with cancer. Rev Infect Dis (1989) 2.16
Trichosporon beigelii infection: a review. Rev Infect Dis (1987) 2.15
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Pirbenicillin, a new semisynthetic penicillin with broad-spectrum activity. Antimicrob Agents Chemother (1976) 2.12
Amoxicillin: in vitro and pharmacological studies. Antimicrob Agents Chemother (1972) 2.12
Infections in cancer patients. Cancer Treat Rev (1975) 2.12
Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis (1996) 2.12
Low infection rate and long durability of nontunneled silastic catheters. A safe and cost-effective alternative for long-term venous access. Arch Intern Med (1993) 2.10
Bacteremia caused by Campylobacter-like organisms in two male homosexuals. Ann Intern Med (1984) 2.07
Systemic candidiasis in cancer patients. Am J Med (1984) 2.05
Comparative in vitro study in new cephalosporins. Antimicrob Agents Chemother (1981) 2.04
Ticarcillin therapy of infections. Antimicrob Agents Chemother (1973) 2.01
Comparative in vitro study of teichomycin A2. Antimicrob Agents Chemother (1983) 2.00
Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med (2000) 1.95
Comparative in vitro activities of teichomycin and other antibiotics against JK diphtheroids. Antimicrob Agents Chemother (1983) 1.93
Klebsiella bacteremia in cancer patients. Am J Med Sci (1973) 1.87
In vitro studies of BB-K8, a new aminoglycoside antibiotic. Antimicrob Agents Chemother (1973) 1.86
A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med (1979) 1.86
The relationship between the thrombotic and infectious complications of central venous catheters. JAMA (1994) 1.85
Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis (1997) 1.84
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol (1987) 1.83
In vitro studies of cefamandole. Antimicrob Agents Chemother (1976) 1.81
Detection of Serratia outbreaks in hospital. Lancet (1976) 1.81
Comparative in vitro activity of cephalosporins. J Antibiot (Tokyo) (1976) 1.79
Infectious complications of indwelling vascular catheters. Clin Infect Dis (1992) 1.77
Serratia sp. infections in cancer patients. Cancer (1970) 1.73
Comparative in vitro study of temocillin (BRL 17421), a new penicillin. Antimicrob Agents Chemother (1982) 1.73
Is a picture worth a thousand medical words? A randomized trial of reporting formats for medical research data. Methods Inf Med (1991) 1.70
Epidemiological studies of Pseudomonas species in patients with leukemia. Am J Med Sci (1970) 1.70
The heart in acute leukemia. A study of 420 autopsy cases. Am J Cardiol (1968) 1.69
Influenza among hospitalized adults with leukemia. Clin Infect Dis (1997) 1.68
Causes of death in adults with acute leukemia. Medicine (Baltimore) (1976) 1.65
Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med (1989) 1.64
Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med (2000) 1.62
Clinical pharmacology of sisomicin. Antimicrob Agents Chemother (1975) 1.61
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med (1973) 1.57
Antibiotics and prevention of microbial colonization of catheters. Antimicrob Agents Chemother (1995) 1.57
Infection in cancer patients. A continuing association. Am J Med (1986) 1.55
Fungal infection and fever of unknown origin in neutropenic patients. Am J Med (1986) 1.54
Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 cases and review. Rev Infect Dis (1992) 1.54
Mycobacteriosis in patients with malignant disease. Arch Intern Med (1976) 1.54
Natural history study of gallbladder cancer: a review of 36 years experience at M. D. Anderson Hospital and Tumor Institute. Cancer (1978) 1.53
In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents. Antimicrob Agents Chemother (1990) 1.52
Effect of broad-spectrum cephalosporins on the microbial flora of recipients. J Infect Dis (1983) 1.52
Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol (1990) 1.51
Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother (1989) 1.51
Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis (1992) 1.50
Protothecosis in patients with cancer: case series and literature review. Clin Microbiol Infect (2003) 1.50
A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J Infect Dis (1994) 1.50
Studies of patients in a laminar air flow unit. Cancer (1969) 1.49
In vitro susceptibilities of Aeromonas hydrophila against new antibiotics. Antimicrob Agents Chemother (1982) 1.48
Bacteremia caused by Aeromonas species in hospitalized cancer patients. Rev Infect Dis (1985) 1.48
In vitro studies of a new semisynthetic penicillin, 6-(d-alpha-sulfoaminophenylacetamido)-penicillanic acid. Appl Microbiol (1969) 1.48
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. N Engl J Med (1974) 1.48
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol (2001) 1.47
Antibiotics in patients with neutropenia. Arch Intern Med (1984) 1.47
Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis (1996) 1.46
In vitro studies of 1-oxacephalosporin (LY 127935), a new beta-lactam antibiotic. Antimicrob Agents Chemother (1980) 1.46
Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol (1998) 1.45
In vitro studies of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother (1985) 1.45
Metastatic patterns of choroidal melanoma. Cancer (1974) 1.45
Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol (1999) 1.45
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45